Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jan 18;104(3):437–440. doi: 10.1038/sj.bjc.6606065

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2011 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of the semi-synthetic flavonoid monoHER on the cytotoxic effects of doxorubicin in the liposarcoma cell line WLS-160. (A) MonoHER pretreatment (50 μM; 1 h) significantly enhances the cell growth inhibition induced by doxorubicin (0.001–0.1 μM; 72 h) (mean±s.d. ^*P⩽0.05 compared with doxorubicin treatment). (B) MonoHER pretreatment (50 μM; 1 h) significantly enhances the apoptosis induced by doxorubicin (10 μM; 6 h) (mean±s.d. ^*P⩽0.05 compared with doxorubicin treatment). Relative light units (RLUs); doxorubicin (DOX). (C) MonoHER treatment (50 μM; 1, 6 and 24 h) has no effect on the intracellular GSH concentration, whereas BSO (50 μM; 1, 6 and 24 h) reduces GSH levels in a time-dependent manner (mean±s.d. ^*P⩽0.05 compared with control). (D) MonoHER pretreatment (50 μM; 1 h) significantly prevents doxorubicin-induced (10 μM; 6 h) NF-κB activation (mean±s.d. ^*P⩽0.05 compared with doxorubicin treatment).